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Abstract: Pancreas ductal adenocarcinoma lacks predictive biomarkers. CD40 is a member of 
the tumor necrosis factor superfamily. CD40–sCD40L interaction is considered to contribute to 
the promotion of tumor cell growth and angiogenesis. The aim of the present study was to inves-
tigate the role of serum sCD40L as a predictor in metastatic pancreatic cancer. We evaluated 27 
consecutive pancreatic cancer patients treated with FOLFIRINOX (21 patients) or gemcitabine 
plus nab-paclitaxel combination (six patients). The sCD40L level was measured in serum by 
enzyme-linked immunosorbent assay at baseline, at first evaluation (all patients), and at time to 
progression (18 patients). The radiological response was evaluated according to the Response 
Evaluation Criteria in Solid Tumors, Version 1.1. The Wilcoxon signed-rank test was used to 
compare pre–post treatment sCD40L levels with respect to clinical response, while Pearson’s 
correlation coefficient was used for the correlation between sCD40L and CA19.9 pre- and post-
treatment. The Kruskal–Wallis test was also conducted for further comparisons. We observed 
a statistically significant reduction in the sCD40L level after 3 months of treatment in patients 
with partial response (11,718.05±7,097.13 pg/mL vs 4,689.42±5,409.96 pg/mL; P,0.01). 
Conversely, in patients with progressive disease, the biomarker statistically increased in the 
same time (9,351.51±7,356.91 pg/mL vs 22,282.92±11,629.35 pg/mL; P,0.01). This trend of 
sCD40L was confirmed in 18 patients at time to progression after the first evaluation. No 
differences were recorded within the stable disease group. Moreover, there was a positive cor-
relation between the sCD40L and CA19.9 pre–post treatment variation percentage (Pearson’s 
correlation coefficient =0.52; P,0.05). Our data suggest a possible predictive role of sCD40L 
in pancreatic cancer patients, similar to CA19.9.
Keywords: pancreatic ductal adenocarcinoma, FOLFIRINOX, gemcitabine plus nab-paclitaxel, 
predictive factor, soluble CD40 ligand
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with poorer prog-
nosis. It is projected to become the second leading cause of cancer death by 2030 with a 
5-year overall survival (OS) rate of ~7%.1,2 At the first diagnosis, only 10%–20% of PDAC 
patients present primarily resectable disease.3 Moreover, even resected patients experi-
ence relapse soon after surgery. In locally advanced, metastatic, and relapsed settings, 
FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine 
plus nab-paclitaxel chemotherapy regimens increase OS, even if prognosis still remains 
unfavorable.4,5 In particular, the four-drug combination regimen FOLFIRINOX has been 
shown to be superior to gemcitabine alone in patients with metastatic PDAC, in terms 
of median OS of 11.1 months in the FOLFIRINOX group as compared to 6.8 months in 
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the gemcitabine group and a median progression-free survival 
(mPFS) of 6.4 months compared to 3.3 months of gemcitabine 
alone.4 Nab-paclitaxel in association with gemcitabine achieved 
a median OS and an mPFS of 8.5 months and 5.5 months, 
respectively.5 In this scenario, many researchers investigated 
the pathophysiologic mechanisms of tumorigenesis of PDAC6 
with the aim to discover new potential diagnostic, prognostic, 
and therapeutic targets.7–9 Moreover, the absence of appropriate 
soluble biomarkers, with the exception of CA19.9,10 hinders 
both early detection and the course of chemotherapy in patients 
with unresectable disease.
CD40L is a cell surface interaction molecule, belonging 
to the tumor necrosis factor family, expressed by T-cells. 
Its interaction with CD40 plays a key role in adaptive 
immune response.11,12 This molecule has been detected in 
a soluble form (sCD40L), produced not only by activated 
T-lymphocytes but also by platelets with proinflamma-
tory and prothrombotic activities.13,14 sCD40L seems to be 
elevated in autoimmune diseases, cardiovascular disorders, 
and cancer.15,16 Furthermore, elevated serum sCD40L levels 
in cancer patients may play an immunosuppressive role.17 
In fact, since myeloid-derived suppressor cells from cancer 
patients express higher levels of CD40, sCD40L acts on 
these cells, allowing an expansion of regulatory T-cells as 
well as an induction of cytokines, such as interleukin-10 
and interleukin-6. Moreover, sCD40L induces a higher 
expression of PD-1 on T-cells, resulting in an activation of 
the immunosuppression system. A previous study reported 
that oxidative stress induces CD40 activation in PDAC 
followed by the enhancement of the production of inflam-
mation cytokines and chemokines influencing the tumor 
microenvironment.17 The clinical significance of sCD40L has 
been recently evaluated in the PDAC patients with respect 
to healthy controls and patients with chronic pancreatitis, 
suggesting serum sCD40L level as a potential prognostic 
biomarker.18 Herein, we evaluated the potential predictive 
role of basal and posttreatment sCD40L serum levels in the 
metastatic PDAC patients receiving first-line chemotherapy 
with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Patients and methods
study population
This is a prospective study enrolling patients from the National 
Cancer Research Centre, Istituto Tumouri “Giovanni Paolo II”, 
Bari, Italy. We considered 27 consecutive chemonaive subjects 
with histologically diagnosed PDAC. The patients were 
treated with FOLFIRINOX (21 patients) or gemcitabine plus 
nab-paclitaxel (six patients) as the first-line chemotherapy. 
The serum levels of CA19.9 and sCD40L were analyzed 
before therapy (baseline) and after 3 months at first evalua-
tion (for all patients). For 18 patients with partial response 
(PR) or stable disease (SD) at first evaluation, the sCD40L 
serum levels were also available and therefore analyzed at 
time to progression. A correlation between the serum levels 
of sCD40L and CA19.9 was also performed. The study was 
approved by the ethics committee of the National Cancer 
Research Centre, Istituto Tumouri “Giovanni Paolo II”, Bari, 
Italy, and written informed consent was obtained from all 
the patients enrolled in the study.
All the records were reviewed, and the following data 
were collected: sex, age, grade of tumor differentiation (G1, 
G2, G3), Eastern Cooperative Oncology Group performance 
status (0–2), chemotherapy regimen (FOLFIRINOX or gem-
citabine plus nab-paclitaxel), and response to chemotherapy 
according to the Response Evaluation Criteria in Solid 
Tumors, Version 1.1.19 
Blood sample collection
Venous blood samples were drawn before therapy (base-
line), after 3 months (all patients), and at progression. Blood 
samples were centrifuged after 30 minutes at 4°C, and serum 
fractions were divided into aliquots, frozen, and stored 
at −80°C until assayed.
serum scD40l and ca19.9 detection
sCD40L serum levels were measured by the Quantikine 
Human CD40 Ligand Immunoassay (R&D Systems, Inc., 
Minneapolis, MN, USA) following the manufacturer’s 
instructions. Optical density was determined using the mul-
tilabel plate reader Victor 3 (PerkinElmer Inc., Waltham, 
MA, USA) set to 450 nm, with a wavelength correction set 
to 540 nm. The concentration of sCD40L, read from the 
standard curve obtained in each experiment and multiplied by 
the dilution factor (1:4), is reported in pg/mL. CA19.9 serum 
levels were tested in certified laboratories (International 
Organization for Standardization 9001:2008) according to 
the manufacturer’s instructions.
statistical analysis
Baseline characteristics of the study population were cal-
culated, and the results were expressed as frequencies and 
percentages. To assess the comparison between pre–post treat-
ment levels of sCD40L and CA19.9, the Wilcoxon signed-
rank test was used, separately for each clinical response. 
In the smaller group of 18 patients, the Kruskal–Wallis 
test was considered to test the differences among sCD40L 
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levels in correspondence to three evaluation moments. The 
analysis was followed by pairwise comparisons. The cor-
relation between sCD40L and CA19.9 in terms of pre–post 
treatment variation was tested using Pearson’s correlation 
coefficient (PCC). The pre–post treatment variation – 
calculated as (value of marker at evaluation − value of 
marker at baseline)/value of marker at baseline ×100 – of 
both clinical markers was also used to identify the patients 
with increasing values and the ones with decreasing val-
ues of sCD40L and CA19.9. These two groups of interest 
were compared in terms of PFS by using the log-rank test. 
The results are graphically presented with Kaplan–Meier 
curves. The multivariate Cox regression model was used to 
investigate the effect of some confounding factors on the 
relationship between sCD40L and CA19.9 levels and clini-
cal response. PFS was defined as the interval between the 
date of diagnosis and disease progression. Receiver operat-
ing characteristic (ROC) curves were performed, for both 
sCD40L and CA19.9, to find the best cutoff value to predict 
PFS at 6 months. Statistical significance was achieved at a 
P-value of ,0.05. All the analyses were performed using the 
R statistical software (Version 3.1.2; R Core Team [2015]. 
R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Twenty-seven consecutive patients with metastatic PDAC 
receiving first-line chemotherapy were evaluated for their 
serum basal and posttreatment sCD40L and CA19.9 levels. 
We considered 19 (70%) males and eight (30%) females with 
a mean age of 63 years. The majority of patients had a poorly 
differentiated (56%) or moderately differentiated (41%) 
adenocarcinoma with a well-performing Eastern Cooperative 
Oncology Group performance status (93% of patients with 
0–1). Twenty-one patients (78%) received FOLFIRINOX 
and six (22%) received gemcitabine plus nab-paclitaxel. PR, 
SD, and PD were observed in 30%, 37%, and 33% patients, 
respectively (Table 1).
chemotherapy-induced changes 
in scD40l and ca19.9 levels and 
response rate
We compared pre- and post-chemotherapy sCD40L and 
CA19.9 levels with clinical response. At a posttreatment 
assessment (first evaluation at 3 months), we observed a statis-
tically significant reduction in the mean pretreatment values of 
serum sCD40L in patients with PR (11,718.05±7,097.13 pg/mL 
vs 4,689.42±5,409.96 pg/mL, P,0.01). Moreover, there was a 
statistically significant increase in the mean pretreatment values 
of serum sCD40L in patients with PD (9,351.51±7,356.91 pg/mL 
vs 22,282.92±11,629.35 pg/mL, P,0.01). There was no statisti-
cal difference in sCD40L among the patients with SD (Table 2). 
Analysis of serum CA19.9 variation was performed, and the 
same trend as in sCD40L variation was detected. It showed that 
the mean values of CA19.9 levels had a significant decrease 
(831.5±984.38 UI/mL vs 355.75±312.09 UI/mL, P,0.01) in 
the PR group and a significant decrease (521.4±694.3 UI/mL vs 
292.7±514.6 UI/mL, P,0.05) in the PD group. In the smaller 
group of 18 patients with an initial PR or SD and with a blood 
test performed at time to progression, the Kruskal–Wallis test 
showed a significant difference (P,0.01) among the three 
evaluations of sCD40L mean levels (Table 3). In particular, the 
pairwise comparisons, calculated on the same data set, revealed 
significant increasing mean values of this biomarker at time to 
progression, considering the mean levels of both the baseline 
(P,0.01) and the first evaluation (P,0.0001; Table 4).
correlation between scD40l and 
ca19.9 levels
We examined a possible relationship between sCD40L 
and CA19.9 levels by conducting a correlation analysis. 
Table 1 Patient characteristics
Patient characteristics Number (%)
number 27
age, years (mean ± standard deviation) 63.85±6.75
sex
Female 8 (29.63)
Male 19 (70.37)
chemotherapy regimen
FOlFirinOX 21 (77.78)
gemcitabine plus nab-paclitaxel 6 (22.22)
ecOg performance status
0 12 (44.44)
1 13 (48.15)
2 2 (7.41)
number of metastatic sites
1 20 (74.07)
$2 7 (25.93)
grading
−1 1 (3.7)
−2 11 (40.74)
−3 15 (55.56)
response
Pr 8 (29.63)
sD 10 (37.04)
PD 9 (33.33)
Abbreviations: ecOg, eastern cooperative Oncology group; Pr, partial response; 
sD, stable disease; PD, progressive disease.
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There was a significant positive correlation (PCC =0.52; 
P,0.01) between the pre- and posttreatment variation of 
these biomarkers (Figure 1).
Pretreatment scD40l and ca19.9 levels 
and progression-free survival
In univariate survival analysis, sCD40L had a signifi-
cant prognostic impact on PFS. mPFS was 5 months and 
8 months for patients with increasing and decreasing values 
of sCD40L, respectively (log-rank P,0.05; Figure 2A). In 
order to clarify these results, multivariate Cox regression 
was performed and the model was adjusted for tumor grade, 
performance status, and number of metastatic sites, consider-
ing they are clinically relevant in the evaluation of response 
to chemotherapy treatment.
The multivariate survival analysis confirmed that sCD40L 
was an independent prognostic factor. In particular, the 
patients with increasing values of this biomarker had a haz-
ard ratio of 2.39 (95% confidence interval [CI]: 1.03–5.56; 
P,0.05; Table 5). The ROC curve analysis showed a cutoff 
point of 10,840 pg/mL with the area under the curve equal 
to 0.65 for PD at 6 months.
The Kaplan–Meier curves and the relative log-rank test 
also showed a significant prognostic impact of CA19.9 on 
PFS. In particular, the median survival time for the groups 
with increasing and decreasing values of this antigen was 
4.5 months and 8 months, respectively (log-rank P,0.05; 
Figure 2B). The multivariate Cox regression confirmed that 
CA19.9 was also an independent prognostic factor. The 
patients with increasing values of the biomarker had a haz-
ard ratio of 4.03 (95% CI: 1.58–10.31; P,0.01; Table 5). 
The confounding factors considered in the model were tumor 
grade, PS, and number of metastatic sites. The ROC curve 
analysis showed a cutoff point of 378 UI/mL with the area 
under the curve equal to 0.52 for PD at 6 months.
Discussion
sCD40L is an 18-kDa trimer produced by activated plate-
lets and T-lymphocytes that binds CD40.20 Literature data 
report that a strong interaction between sCD40L and CD40 
expressed on neoplastic cells induces apoptosis, whereas the 
low ligation signal of sCD40L could increase proliferation and 
angiogenesis.21 Moreover, this ligand appears to have diagnos-
tic relevance in cancer. In fact, its serum levels have been found 
to be more elevated in advanced breast, colorectal, and prostate 
cancer patients with respect to healthy donors from ~10 ng/mL 
to ~0 ng/mL.22 In addition, sCD40L levels were significantly 
lowered in hormone refractory prostate cancer after treatment 
with ketoconazole and alendronate. This suggests a potential 
predictive role of sCD40L in this malignancy.16–18,20,21,23
In vitro and in vivo studies display a crucial involvement 
of the CD40 pathway in regulating the immune reaction and 
fibrosis in PDAC, a tumor with a strong interaction between 
cancer cells and microenvironment.24 The clinical signifi-
cance of serum sCD40L as a potential diagnostic and prog-
nostic biomarker in patients with PDAC has been recently 
reported.17 Chung and Lim demonstrated that the serum 
sCD40L levels were significantly increased in the PDAC 
group compared with the healthy and chronic pancreatitis 
groups. Moreover, they demonstrated that patients with high 
serum sCD40L had a poorer prognosis with respect to low 
serum sCD40L. The authors showed a potential diagnostic/
Table 2 comparison between pre- and posttreatment scD40l and ca19.9 levels in different groups of response to therapy
Number of  
patients
Pre-treatment  
(mean ± standard deviation)
Posttreatment  
(mean ± standard deviation)
P-value
scD40l
Pr 8 11,718.05±7,097.13 pg/ml 4,689.42±5,409.96 pg/ml ,0.01
sD 10 11,774.15±6,133.25 pg/ml 12,102.05±7,358.17 pg/ml ns
PD 9 9,351.51±7,356.91 pg/ml 22,282.92±11,629.35 pg/ml ,0.01
ca19.9
Pr 8 831.5±984.38 iU/ml 355.75±312.09 Ui/ml ,0.01
sD 10 521.4±694.3 iU/ml 292.7±514.6 Ui/ml ns
PD 9 2,569.67±4,816.04 Ui/ml 3,384.44±6,183.87 Ui/ml ,0.05
Abbreviations: PR, partial response; SD, stable disease; ns, not significant; PD, progressive disease.
Table 3 Results of Kruskal–Wallis test: sCD40L levels in baseline, first evaluation, and progression
Number of  
patients
Baseline  
(mean ± standard deviation)
First evaluation  
(mean ± standard deviation)
Progression  
(mean ± standard deviation)
P-value
Pr + sD 18 11,749.21±6,376.19 pg/ml 8,807.54±7,421.61 pg/ml 20,292.7±12,663.98 pg/ml ,0.01
Abbreviations: Pr, partial response; sD, stable disease.
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prognostic role of sCD40L.18 On the other hand, we focused 
on the predictive role of this biomarker.
In the present study, we prospectively analyzed the trend 
of sCD40L at baseline, after 3 months of therapy, and at 
progression in 27 metastatic PDAC patients treated with 
FOLFIRINOX or gemcitabine plus nab-paclitaxel chemo-
therapy regimens. We demonstrated a significant relation 
between sCD40L serum-level reduction and response to ther-
apy in the absence of statistical differences in patients with 
SD at the first evaluation. Furthermore, the serum levels of 
sCD40L were significantly related to progression of disease 
in both the nine chemoresistant patients and the 18 initially 
responsive patients. The trend of increase in progression was 
significantly confirmed in the group of 18 patients by means 
of Kruskal–Wallis and subsequent pairwise comparisons. 
According to these results, we suggest that serum sCD40L 
levels could play a predictive role regarding the response to 
the first line treatment in advanced PDAC.
At the same time, evaluation of level changes of serum 
CA19.9 confirmed its predictive role in patients with both 
PD and PR.10 Moreover, PCC showed a statistically signifi-
cant correlation between serum-level variations of these two 
molecules, demonstrating that sCD40L might have the same 
predictive value as CA19.9.
The univariate analysis confirmed that a decrease in 
serum sCD40L is predictive of a longer mPFS (8 months) 
despite the increase that predicts a short mPFS (5 months). 
The multivariate analysis showed that this biomarker is an 
independent factor.
Figure 1 correlation between the scD40l and ca19.9 pre–post treatment 
variations (%).
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???
??
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Table 4 Pairwise comparisons: evaluation of differences in 
sCD40L levels at baseline, first evaluation, and progression
Pairwise comparisons P-value
Baseline vs first evaluation ns
Baseline vs progression ,0.01
First evaluation vs progression ,0.0001
Abbreviation: ns, not significant.
Figure 2 The Kaplan–Meier curves reveal that the patients with increasing values 
of sCD40L have a PFS significantly lower than that of the patients with decreasing 
values of the same biomarker (log-rank ,0.05).
Notes: Kaplan–Meier curves of PFs according to (A) scD40l variations and (B) 
ca19.9 variations.
Abbreviation: PFs, progression-free survival.
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Table 5 results of multiple cox regression
Variable PFS
HR (95% CI) P-value
scD40l (increasing vs decreasing) 2.39 (1.03–5.56) ,0.05
ca19.9 (increasing vs decreasing) 4.03 (1.58–10.31) ,0.01
Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence 
interval.
If we consider these results and the crucial role of sCD40L 
in cancer microenvironment, this biomarker could be useful 
in a stromal tumor such as PDAC, not forgetting that CA19.9 
is negative in ~20% of PDAC patients,24 as found in six of 
our patients.
In addition, other roles for CD40L are described in the 
literature, such as its immunosuppressive role (ie, HIV 
infection).10 In particular, Beatty et al25 demonstrated the 
role of the CD40 pathway in regulating the immune reaction 
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in PDAC by recruitment of tumor-associated macrophages. 
They showed that the CD40 pathway can be therapeutically 
targeted to restore tumor immune surveillance by stromal 
tumor-associated macrophages. According to preclinical 
data, a Phase I trial of an agonist CD40 monoclonal antibody 
combination with gemcitabine reported a good safety profile 
with a PR for four of seven patients.26 An immunosuppres-
sive effect of sCD40L, similar to an immunocheckpoint, has 
been hypothesized.
Conclusion
Although the small number of patients considered limits 
the interpretation of our data, we suggest that sCD40L may 
be a reliable predictive biomarker, potentially useful in 
the composition of the complex biological scenario of this 
malignancy.
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